scispace - formally typeset
Y

Yasuhiko Minokoshi

Researcher at National Institutes of Natural Sciences, Japan

Publications -  104
Citations -  16619

Yasuhiko Minokoshi is an academic researcher from National Institutes of Natural Sciences, Japan. The author has contributed to research in topics: Brown adipose tissue & Leptin. The author has an hindex of 48, co-authored 101 publications receiving 15494 citations. Previous affiliations of Yasuhiko Minokoshi include Graduate University for Advanced Studies & Beth Israel Deaconess Medical Center.

Papers
More filters
Journal ArticleDOI

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

TL;DR: It is shown that phosphorylation and activation of the 5′-AMP-activated protein kinase (AMPK) are stimulated with globular and full-length Ad in skeletal muscle and only with full- lengths Ad in the liver, indicating that stimulation of glucose utilization and fatty-acid oxidation by Ad occurs through activation of AMPK.
Journal ArticleDOI

Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase.

TL;DR: It is shown that leptin selectively stimulates phosphorylation and activation of the α2 catalytic subunit of AMPK (α2 AMPK) in skeletal muscle, thus establishing a previously unknown signalling pathway for leptin, and identifying AMPK as a principal mediator of the effects of leptin on fatty-acid metabolism in muscle.
Journal ArticleDOI

AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus

TL;DR: Hypothalamic AMPK plays a critical role in hormonal and nutrient-derived anorexigenic and orexigenic signals and in energy balance, and inhibition of hypothalamic AM PK is necessary for leptin's effects on food intake and body weight, as constitutively active AMPK blocks these effects.
Journal ArticleDOI

PTP1B regulates leptin signal transduction in vivo.

TL;DR: It is shown that PTP1B regulates leptin signaling in vivo, likely by targeting Jak2, and may be a novel target to treat leptin resistance in obesity.